LBPH Longboard Full Business Value

Official company branding of longboardpharma.com (LBPH)

Longboard Pharmaceuticals specializes in developing epilepsy treatments, leveraging partnerships with scientific centers to accelerate commercialization. Market price action on GURU.Markets shows an Enterprise Value of . The high business valuation is driven by patents and promising bexicaserin trials, making the company's biotechnological foundation one of the most defensive assets in its segment.

LBPH (Longboard) Total Company Value history from 07/04/2022 to 10/29/2026

Longboard Pharmaceuticals (LBPH) - metric breakdowns and financial figures

- price and consensus price forecast:
Price Chart Longboard Pharmaceuticals Inc|LBPH - Price Target Chart
- market capitalization data:
Market Valuation Longboard Pharmaceuticals|LBPH - Enterprise Value
- book capitalization data:
Accounting Value of a Share Longboard Pharmaceuticals|LBPH - Company Book Value|Capitalization to Book Value Ratio longboardpharma.com|LBPH - Company Total Assets
- debt and liquidity data:
Debt to Capital Longboard Pharmaceuticals|LBPH - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital longboardpharma.com|LBPH - Company Debts|Debt to Net Assets Ratio Longboard Pharmaceuticals|LBPH - Company Long-Term Debt|Short-Term Debt Longboard Pharmaceuticals
Comprehensive company analysis:Longboard Pharmaceuticals Inc (LBPH)
Mass-produced product of Longboard Pharmaceuticals

For the research-intensive biotech Longboard Pharmaceuticals (LBPH), which attracts neurobiologists through stock options and premium payouts, this indicator reflects the aggregate value of intellectual capital and infrastructure. Analyzing the core business value, an investor sees the actual acquisition price of Longboard Pharmaceuticals (LBPH) via the sum of market capitalization and debt minus cash, allowing for an assessment of the asset's fundamental value adjusted for net debt.

Direct competitors

Biogen Inc - Total Company Value|Total Company Value Neurocrine Biosciences Inc|RGC - Full Business Value|Enterprise Value Axsome Therapeutics AXSM|ACAD (acadia-pharm.com) - Value Adjusted for Debt and Cash|Total Company Value Xenon (XENE)|Business Value Viking Therapeutics Inc|Supernus Pharma - Enterprise Value|Total Enterprise Value Catalyst Corp CPRX|Real Price to Acquire Entire Company DNLI (Denali Therapeutics)|harmonybiosciences.com - Enterprise Value|Total Company Value Biohaven (BHVN)|AMLX: Value Adjusted for Debt and Cash|Total Company Value TRVI|PRAX (Praxis Corp) - Total Enterprise Value|Total Company Value Anavex Life Sciences|Total Company Value CBLL|Prothena Biosciences - Total Company Value|Total Enterprise Value ALEC (alector.com)|ANNX - Total Company Value|Business Value Omeros Corp OMER|Enterprise Value NGNE|ACIU - Full Takeover Company Value|Voyager Therapeutics, Inc. (VYGR) - Enterprise Value|NMRA (Neumora) - Total Company Value|Total Company Value SCLX (Scilex Holding Co.)|Total Enterprise Value Tevogen Bio Inc.|Enterprise Value ACOG|Enterprise Value CGTX (Cognition Therapeutics Inc.)|Total Company Value Inhibikase Therapeutics, Inc.|Value Adjusted for Debt and Cash Cassava Sciences Inc SAVA|Assertio Therapeutics (ASRT) - Enterprise Value|Coya Therapeutics, Inc. (COYA) - Business Value|Real Price to Acquire Entire Company vistagen.com VTGN|OVID (Ovid Therapeutics) - Value Adjusted for Debt and Cash|Total Company Value Acumen Pharmaceuticals, Inc. ABOS|Full Business Value CervoMed, Inc.|Alterity Therapeutics (ATHE) - Enterprise Value|Value Adjusted for Debt and Cash clene.com (CLNN)|Enterprise Value PEPG (PepGen)|Jupiter Neurosciences, Inc. - Enterprise Value|Total Company Value Relmada Therapeutics, Inc. (RLMD)|ANVS: Value Adjusted for Debt and Cash|GRCE (gracetx.com) - Total Company Value|Firefly Neuro (AIFF) - Real Price to Acquire Entire Company|KLTO (ANEW Medical) - Enterprise Value|Enterprise Value NeuroSense Therapeutics, Ltd.|Enterprise Value RVPH (Reviva Pharmaceuticals Holdings, Inc.)|Real Price to Acquire Entire Company metaviatx.com (MTVA)|NRXS: Enterprise Value|HSDT - Total Enterprise Value|Passage Bio Corp - Real Price to Acquire Entire Company|Neuphoria Therapeutics Inc. (NEUP) - Enterprise Value|NERV - Real Price to Acquire Entire Company|Athira Pharma Inc (ATHA) - Aggregate Business Value|ADXN: Enterprise Value|Company Buyout Price Alzamend|Enterprise Value CYCN (Cyclerion Therapeutics)|Real Price to Acquire Entire Company protagenic.com (PTIX)|Enterprise Value KTTA (Pasithea Therapeutics Corp.)|Cortigent Inc - Enterprise Value|ATXI - Total Company Value|BCLI: Total Company Value|Cara Therapeutics, Inc. - Total Company Value|CHRO (chromocell.com) - Company Buyout Price|Total Company Value Eliem Therapeutics, Inc.|Total Company Value Intra-Cellular|Enterprise Value Marinus (MRNS)|Total Company Value NKGN (NKGen Biotech Corp)|NeuroBo Pharmaceuticals (NRBO) - Total Company Value|Full Business Value sagerx.com SAGE|Enterprise Value Synaptogenix (SNPX)|TRVN: Value Adjusted for Debt and Cash|Total Company Value vigilneuro.com|anewmeds.com (WENA) - Business Value|Enterprise Value CERE (Cerevel Therapeutics)